Literature DB >> 11790528

A closer look at proteolysis and MHC-class-II-restricted antigen presentation.

Ana-Maria Lennon-Duménil1, Arnold H Bakker, Paula Wolf-Bryant, Hidde L Ploegh, Cécile Lagaudrière-Gesbert.   

Abstract

Antigen presentation by MHC class II molecules relies on the action of endocytic proteases, which are differentially expressed in antigen-presenting cells and are regulated by different components of the immune system. Endocytic enzymes process and convert exogenous antigens into peptidic determinants capable of interaction with MHC class II molecules. Chemical and genetic tools have recently been developed to study the role of lysosomal proteases in antigen presentation.

Mesh:

Substances:

Year:  2002        PMID: 11790528     DOI: 10.1016/s0952-7915(01)00293-x

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  34 in total

1.  Empty class II major histocompatibility complex created by peptide photolysis establishes the role of DM in peptide association.

Authors:  Gijsbert M Grotenbreg; Melissa J Nicholson; Kevin D Fowler; Kathrin Wilbuer; Leah Octavio; Maxine Yang; Arup K Chakraborty; Hidde L Ploegh; Kai W Wucherpfennig
Journal:  J Biol Chem       Date:  2007-05-24       Impact factor: 5.157

2.  Syk-dependent actin dynamics regulate endocytic trafficking and processing of antigens internalized through the B-cell receptor.

Authors:  Delphine Le Roux; Danielle Lankar; Maria-Isabel Yuseff; Fulvia Vascotto; Takeaki Yokozeki; Gabrielle Faure-André; Evelyne Mougneau; Nicolas Glaichenhaus; Bénédicte Manoury; Christian Bonnerot; Ana-Maria Lennon-Duménil
Journal:  Mol Biol Cell       Date:  2007-06-27       Impact factor: 4.138

3.  Healthy individuals have Goodpasture autoantigen-reactive T cells.

Authors:  Juan Zou; Sigrid Hannier; Lindsay S Cairns; Robert N Barker; Andrew J Rees; A Neil Turner; Richard G Phelps
Journal:  J Am Soc Nephrol       Date:  2008-01-23       Impact factor: 10.121

4.  Relaxin enhances the oncogenic potential of human thyroid carcinoma cells.

Authors:  Sabine Hombach-Klonisch; Joanna Bialek; Bogusz Trojanowicz; Ekkehard Weber; Hans-Jürgen Holzhausen; Josh D Silvertown; Alastair J Summerlee; Henning Dralle; Cuong Hoang-Vu; Thomas Klonisch
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

5.  DNA-vaccine platform development against H1N1 subtype of swine influenza A viruses.

Authors:  Huiling Wei; Stephen D Lenz; David H Thompson; Roman M Pogranichniy
Journal:  Viral Immunol       Date:  2012-07-20       Impact factor: 2.257

6.  Species-specific class I gene expansions formed the telomeric 1 mb of the mouse major histocompatibility complex.

Authors:  Toyoyuki Takada; Attila Kumánovics; Claire Amadou; Masayasu Yoshino; Elsy P Jones; Maria Athanasiou; Glen A Evans; Kirsten Fischer Lindahl
Journal:  Genome Res       Date:  2003-04       Impact factor: 9.043

7.  Cathepsin L is essential for onset of autoimmune diabetes in NOD mice.

Authors:  René Maehr; Justine D Mintern; Ann E Herman; Ana-Maria Lennon-Duménil; Diane Mathis; Christophe Benoist; Hidde L Ploegh
Journal:  J Clin Invest       Date:  2005-09-22       Impact factor: 14.808

8.  Evaluating the intrinsic cysteine redox-dependent states of the A-chain of human insulin using NMR spectroscopy, quantum chemical calculations, and mass spectrometry.

Authors:  Alok K Sharma; Yan Ling; Allison B Greer; David A Hafler; Sally C Kent; Yong Zhang; Alan C Rigby
Journal:  J Phys Chem B       Date:  2010-01-14       Impact factor: 2.991

9.  Production of tag-free recombinant fusion protein encompassing promiscuous T cell epitope of tetanus toxoid and dog zona pellucida glycoprotein-3 for contraceptive vaccine development.

Authors:  Neha Gupta; Abhinav Shrestha; Amulya Kumar Panda; Satish Kumar Gupta
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

10.  Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma.

Authors:  Oliver G Goldstein; Laela M Hajiaghamohseni; Shereen Amria; Kumaran Sundaram; Sakamuri V Reddy; Azizul Haque
Journal:  Cancer Immunol Immunother       Date:  2008-03-15       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.